UE Lifesciences Unveils iBreastExam for Early Breast Cancer Detection

The scanner is designed for use by frontline healthcare workers after minimal training, eliminating the need for specialized expertise or data interpretation.

Mumbai-based UE LifeSciences has launched iBreastExam, a palm-sized, non-invasive hand-held device that is making early detection of breast cancer quick.

According to the company, the newly launched device is ultra-portable, painless and radiation-free, requires minimal training to operate, works offline and offers instant results with high efficacy. 

Gauri Navalkar Godse, director and CEO, India, UE LifeSciences said, “With over 1.2 million women screened, iBreastExam is significantly impacting equitable access to vital early detection, regardless of location or socioeconomic status, and is paving the way for a future where early detection is accessible to all.”

About the AI-Powered Breast Cancer Screening Tool

The iBreastExam uses Co-Planar sensors to evaluate tissue elasticity and detect potential abnormalities electronically by analyzing the resistance levels encountered during the scan. The device can quickly identify areas of concern that may require further evaluation. 

According to Godse, the device pairs with a tablet via Bluetooth, followed by brief air and tissue calibrations. The user then gently scans the breast in small quadrants, guided by the app, with the entire process taking approximately eight minutes for both breasts. 

Additionally, the results are captured in real-time on a mobile app, providing immediate, point-of-care feedback.

iBreastExam has been deployed through impactful collaborations, including reaching over 110,000 women through the Swasth Mahila, Swasth Goa Project, and a partnership with Hinduja Hospital to screen Mumbai police women.

Future Plans 

Looking ahead, UE LifeSciences is launching a ‘Think Pink’ campaign, an urban-private market programme aimed at reaching 100 million women in the top 100 cities in emerging markets, offering cost-effective iBreastExam screenings. 

To further expand its reach, the company is also developing solutions for the early detection of oral and cervical cancers, creating a community health worker-led programme for the early detection and management of three prevalent types of cancer.

These devices are integrated into the RaKSA initiative, a community health worker-led program that enables simultaneous screening for breast, cervical, and oral cancers in a single visit, improving accessibility, early diagnosis, and management of these prevalent cancers worldwide.

UE LifeSciences, a healthtech company, focuses on innovating cancer detection to make it more accessible via its flagship products, iBreastExam and cervAIcal, which use patented, AI-enhanced technologies to provide effective screening solutions. 

Apart from its new launch, iBreastExam, UE LifeSciences also launched cervAIcal in 2024. Like iBreastExam, the device is an AI-enabled mobile colposcopy for cervical cancer screening designed to be used in diverse settings, from clinics to remote locations.

UE LifeSciences recently partnered with the Shri Basanagouda Malipatil Ukkinal Charitable Trust and Glenmark Pharmaceuticals to conduct a triple cancer screening camp in Karnataka, screening over 300 patients for breast, cervical, and oral cancers. 

Further, with two days of breast health screening in Guwahati, UE LifeSciences collaborated with Glenmark Pharmaceuticals to conduct iBreastExam camps at Narayana Health and NEMCARE Hospitals.

Stay tuned for more such updates on Digital Health News.

Stay tuned for more such updates on Digital Health News